Madrigal Pharmaceuticals, Inc.

MDGL Healthcare Biotechnology

Madrigal Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $958.4 million, up 432.1% from fiscal 2024. In the quarter to June 2026, revenue grew 71.2%, EPS fell 32.9%, free cash flow grew 140.5% and total debt rose 187.9%, each against the same quarter a year earlier.

449.74 10.07 −2.19%
Market cap
$10.6B
P/E
0.0×
Fwd P/E
−71.3×
Dividend yield
—
F-score
n/a
Altman Z
10.48
Beneish M
0.50
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
0.00 0.00 0.00 0.00

+8 more quarters

P/S ratio
12.19 13.42 13.63 13.92
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
670.81 (90.77) (97.89) 129.14
P/B ratio
29.88 27.96 21.68 16.48
EV/Sales
11.80 13.00 12.95 12.88
EV/EBITDA
0.00 0.00 0.00 0.00
EV/FCF
(72.40) (53.41) (64.00) (57.61)
Current Ratio
3.20 3.50 4.01 3.44
Net Debt/EBITDA
9.09 5.22 11.34 6.94
Debt/Equity
0.65 0.63 0.56 0.54
Earnings Yield
(2.40%) (2.37%) (2.02%) (2.59%)
Free Cash Flow Yield
(1.34%) (1.81%) (1.48%) (1.61%)
Free Cash Flow per Share
0.65 (5.90) (5.93) 3.38
Book value per Share
17.97 18.72 26.87 27.83
Free Cash Flow
19.08 (171.28) (133.07) 75.99
EV/EBIT
0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates